Korro Bio Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from_____________________to_____________________Commission File Number: 001-39062 Korro Bio, Inc. (Exact name of registrant as specified in its charter) 02141(Zip Code) (617) 468-1999 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 4, 2026, the registrant had 14,422,571 shares of common stock, $0.001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive LossCondensed Consolidated Statements of Stockholders’ EquityCondensed Consolidated Statements of Cash FlowsNotes to Unaudited Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal Proceedings26Item 1A.Risk Factors26Item 2.Unregistered Sales of Equity Securities and Use of Proceeds73Item 3.Defaults Upon Senior Securities73Item 4.Mine Safety Disclosures73Item 5.Other Information73Item 6.Exhibits74Signatures75 Unless the context otherwise indicates, references in this Quarterly Report on Form 10-Q to the “Company,” the "combinedcompany," “we,” “our” and “us” refer, collectively, to Korro Bio, Inc., a Delaware corporation, and its consolidated subsidiaries(including Legacy Korro) after completion of our November 2023 business combination. The term “Legacy Korro” refers toprivately held Korro Bio Ops, Inc. (formerly known as Korro Bio, Inc.), which we acquired in the November 2023 businesscombination. We use various trademarks and trade names in our business, including without limitation our corporate name and logo. Allother trademarks or trade names referred to in this Quarterly Report on Form 10-Q are the property of their respective owners.Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q may be referred to without the ®and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to thefullest extent under applicable law, their rights thereto. In this Quarterly Report on Form 10-Q, when we refer to our leads or lead candidates, we are referring to ouroligonucleotides that we are researching for potential nomination as a development candidate. When we refer to our developmentcandidates, we generally mean an oligonucleotide lead candidate that we have nominated for clinical development. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or this Quarterly Report, includes statements that are not historical facts and areconsidered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act,and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our forward-looking statementsinclude, but are not limited to, express or implied statements regarding our or our management team’s expectations, hopes, beliefs,intentions or strategies regarding the futu